PDGFA and phyllodes tumor: Overexpression of EGFR and PDGFA is also present in malignant phyllodes tumors, which suggests the potential use of dual VEGFR/EGFR inhibitors (Vandetanib), a combination of anti-VEGFR and anti-EGFR and multikinase inhibitors (Panzopnib).